VivoSeq
Other

Kidney Injury

21

Pipeline Programs↗

3

Active Trials↗

12

Companies Involved↗

Kidney Injury is an emerging landscape with 21 programs across 12 companies. The most active players are Action Pharma A/S, Omnivium, Gilead. 2 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

23/100

Completion Rate

60/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Action Pharma A/S

1 program

Phase 2O

Omnivium

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2L

La Jolla Pharmaceutical Company

1 program

Phase 2Novartis logo

Novartis

2 programs

Phase 3N

Neurim Pharmaceuticals Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

16

clinical trials

Completed6 · 38%
Unknown status3 · 19%
Terminated3 · 19%
Not yet recruiting1 · 6%
Active, not recruiting1 · 6%
Withdrawn1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

16 trials

Melatonin for Prevention of Kidney Injury
Recruiting·RRutgers, The State University of New Jersey·Phase 3·NCT05084196·300 enrolled
Cisplatin Disposition and Kidney Injury
Active, not recruiting·UUniversity of Colorado, Denver·Phase 3·NCT03817970·72 enrolled
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Not yet recruiting·FFakultas Kedokteran Universitas Indonesia·Phase 2/3·NCT07156786·72 enrolled
The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery
Completed·SSeoul National University Hospital·N/A·NCT02599155·200 enrolled
Prevention of Akute Kidney Injury, Hearttransplant, ANP
Completed·SSahlgrenska University Hospital·Phase 3·NCT02665377·86 enrolled
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
Completed·AAction Pharma A/S·Phase 2·NCT01256372·77 enrolled
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
Completed·CComplexa, Inc.·Phase 1·NCT02248051·12 enrolled
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Completed·VVirginia Commonwealth University·N/A·NCT00308906·166 enrolled
The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats
Completed·—·N/A·NCT07094165·28 enrolled
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
Terminated·DDurect·Phase 2·NCT04447404·2 enrolled
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT04051957·9 enrolled
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects
Terminated·AAlloCure Inc.·Phase 2·NCT01602328·156 enrolled
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02882373
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
Unknown status·—·Phase 2·NCT04450095·30 enrolled
Angiotensin in Septic Kidney Injury Trial
Unknown status·AAustin Health·Phase 2·NCT00711789·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)